AU2012241407B2 - Modified release pharmaceutical compositions of Desvenlafaxine - Google Patents

Abstract

This present invention relates to modified release pharmaceutical composition comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof. More particularly, the invention relates to modified release pharmaceutical compositions comprising Desvenlafaxine Benzoate and a process for preparation thereof. Further, the invention relates to a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof wherein C

Description

WO 2012/140577 PCT/IB2012/051761 1 MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS OF DESVENLAFAXINE Field Of The Invention: This present invention relates to modified release pharmaceutical compositions 5 comprising Desvenlafaxine and a process for preparation thereof. Background Of The Invention: Serotonin-norepinephrine reuptake inhibitors (SNRLs) are a class of antidepressant drugs used in the treatment of major depression and other mood disorders. They are also used to treat anxiety disorders, obsessive-compulsive disorder (OCD), attention deficit 10 hyperactivity disorder (ADHD), chronic neuropathic pain, fibromyalgia syndrome (FMS), and for the relief of menopausal symptoms. Serotonin-norepinephrine reuptake inhibitors (SNRls) include but not limited to venlafaxine, Desvenlafaxine, milnacipran, duloxetine, sibutramine, levomilnacipran and sibutramine. 15 Desvenlafaxine is Serotonin-norepinephrine reuptake inhibitors and chemically, Desvenlafaxine is chemically named (±)-1-[2-(dimethylamino)-1-(4 hydroxyphenyl)ethyl]cyclohexanol, is a major metabolite of venlafaxine and has been shown to inhibit norepinephrine and serotonin uptake. Desvenlafaxine, which can also be referred to as O-Desniethylvenlafaxine or desmethylvenlafaxine, is represented by the 20 following structural formula: WO 20121140577 PCT/IB2012/051761 2 0-desmethyl venlafaxine is a major metabolite of venlafaxine and has been shown to inhibit norepinephrine and serotonin uptake. Desvenlafaxine was exemplified as a fumarate salt in U.S. Pat. No. 4,535,186. However, the fumarate salt of 0-desmethyl-venlafaxine has unsuitable physicochemical and 5 permeability characteristics. 0-desmethyl-venlafaxine is also exemplified as a free base in International Patent Publication No. WO 00/32555. U.S. Pat. No. 6,673,838 disclose different crystalline forms of Desvenlafaxine Succinate mainly Form I, II, III and IV. Further it discloses amorphous form of Desvenlafaxine Succinate. U.S. Pat. No. 7,820,716 discloses Form V and Form F of Desvenlafaxine 10 Succinate. Different salts of Desvenlafaxine have been disclosed in the literature. Succinate salt (U.S. Pat. No. 6,673,838 and US Patent Application No. 20040106576); formate (U.S. Pat. No.7,001,920); hydrochloride (AU Patent Application No. 20080218997); citrate, maleate, mesylate, mandelate, quinic acid salt and tartrate (WO 2010008735); phosphate 15 (WO 2009136756); D-glucuronate and orotate (WO 2009095431); oxalate, Benzoate and lactate (WO 2009053840); saccharinate (WO 2009017813). Salt formation provides a means of altering the physicochemical and resultant biological characteristics of a drug without modifying its chemical structure. A salt form can have a dramatic influence on the properties of the drug. The selection of a suitable salt is 20 partially dictated by yield, rate and quantity of the crystalline structure. In addition, hygroscopicity, stability, solubility and the process profile of the salt form are important considerations. The identification of a salt form that exhibits a suitable combination of properties can be difficult. The Succinate monohydrate form of Desvenlafaxine has been incorporated into an 25 extended release hydro-gel tablet, which reduces adverse effects such as nausea, vomiting, diarrhea, and abdominal pain. Formulations describing the use of hydroxypropyl methylcellulose (HPMC) as the hydrogel matrix have been described in U.S. Pat. No. 7,291,347.

3 US Patent Application No 20050175698 provides an enteric coated multiparticulate form of Desvenlafaxine that reduces undesirable characteristics associated with Desvenlafaxine and the hydrogel formulation thereof. These Desvenlafaxine multiparticulates are composed of Desvenlafaxine Succinate, Desvenlafaxine format, or combinations thereof. Advantageously this formulation also allows more convenient dosing to patients who have difficulty swallowing solid foods. US Patent Application No 20100210719 describes stable amorphous 0 desmethylvenlafaxine Succinate solid dispersions with one or more pharmaceutically acceptable carriers. US Patent Applcation No 20100330172dislose arix controlle release pharmaceutical formulation comprising Desenlafaxine Succinate, having an MlE of between about 5 micrometer and about 100 micrometer and marx rate-controlling pharmaceuticallycceptable polymer US Patent Application No 20110046231 provides pharmaceutical composition comprising a solid state form of O-desmethylveniafaxine salt and one or more pharmaceutically acceptable recipients, wherein the salt of 0 desmethyivenlafaxine is an oxalate salt, a Benzoate salt or a lactate salt. US Patent Application No 20070014859 discloses superbioavailable DVS (0-desmethylvenlafaxine Succinate) sustained release composition comprising a core containing at least DVS and a water insoluble filler in an oral dosage unit having a delayed release of at least about one hour and a sustained release over multiple hours toprovide a total release of greater than about 85% within about 12 to about 14 hours. he there are many compositions available to reduce side effects of conventional dosage forms, still there remains a need to develop a controlled release composition of Desvenlafaxine.

4 Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present disclosure as it existed before the priority date of each claim of this application. Embodiment Of The Invention: The present invention relates to modified release pharmaceutical compositions comprising Desve nafaxine. One aspect of the invention is modifed release pharmaceutical compositions comprising Desvenlafaxine one or more release modifying agents) and one or more pharmaceutical acceptable excpient s thereofE Another aspect of the invention is modified release pharmaceutical compositions comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s, wherein ds 5 particle size of Desvenlafaxine is up to about 80 microns. Another aspect of the invention is modified release pharmaceutical compositions comprising Desve nlafaxine, one or more release modifying agents) and one or more pharmaceutically acceptable excipient(s), wherein composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0% NaCin water at 100 rpm. Another aspect of the invention is modified release pharmaceutical compositions comprising Desvenlafaxine, one or more release modifying agents) and one or more pharmaceutically acceptable excipient(s), wherein d 5 0 particle size of Desvenlafaxine is up to about 80 microns such that composition releases about 75% of Desveniafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.

Another aspect of the invention is modified release pharmaceutical composition comprising a matrix core comprising Desvenlafaxine, one or more release modifying agents) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agents) and one or more pharmaceutically acceptable excipient(s). Another aspect of the invention is modined release pharmaceutical composition comprising a matrix core comprising Desvenlafaxine, one or more release modifying agents) and one or more pharmaceuticals acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agents) and one or more pharmaceutically acceptable excipient(s), such that ds 0 particle size of Desvenlafaxine up to about 80 microns, Another aspect of the invendon is modified release pharmaceutical composition comprising a mazix core comprising Desvenlafaxine, one or more release modifying agents and one ormore pharmaceutically acceptable excipient(s wherein the matrix core being further coatedwith one or more relase modifying agent(s) and oneor more pharmaceutcally aceptable excipiens herein composition releases about 75% of Desenlafa1n3 e in 16 hour measured using USP TypeI dissolution apparatus in 900 ml of 0.9% Naai in water at 100 rpm Another aspect of the invention is modified release pharmaceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agents) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agents) and one or more pharmaceutically acceptable excipient(s), wherein d 5 0 particle size of Desvenlafaxine is up to about 80 microns such that composition releases about 75% of Desveniafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCI in water at 100 rpm.

Summary Of The invention: The present invemion provides modified release pharmaceutical compositions comprising Desvenlafaxne and a process for preparation thereof and their use in medicines. The invention relates to modified release pharmaceutical compositions comprising Desvenlafaxine Benzoatene ormore release modifying agents) and one or more pharmaceuticals acceptable excipienjs) thereof, which is bioequivalenz to extended release position of Desveniafaxine Succinate in a bioavaiiabi study in humans. Further C and AUC of themodiied release composition comprising Desvenlafaxine Benzoate are independent of food effect. fn one aspet of the invention there is provided a modined release pharmaceutical omposition comprising Desveniafaxine Benzoate one or more release modifying agents) and one or nmore pharmaceutically acceptable excipien4s) thereof. wherein Desvenlafaxie Benzoate is characterized by a powder X-ray diffraction patternhaving at least one peak at about 5.4, 1075, 66, 98.0, 19.2, 2332 = 0.2 degrees 20, in another aspect of the invention there is prv aided a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agents) and one or more pharmaceutically acceptable excipient(s) thereof, wherein said composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaC in water, at 100 rpm, In yet another aspect of the invenion there s provided a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one ormore release modifying agents) and one or more pharmaceutical acceptable excipient~s) thereof, wherein C,: and AUC of the modinedrlease composition are withn the lmit of 80 4 to 125 % of Ca and AUG ofthe extended ease compsion of Desveniafaxne Succinate 6A In sti another aspect of the invention there is provided a modified release pharmaceutical composition omprisng Desenlafaxine Benzoate, one or more relase modifying agents) and one or more pharmaceuticaly acceptabe excipientr wtheof,he modied release composition are independent of food effect Detailed Description Of Theinention It wil be understood that, fo the purposes of invention, Desvenafaxine may be used in the form of base, pharmaceuceally acceptable sats) or enantomer(s) or polymorph~s thereof. Throughout this specification the wordcomprise or variations such as 'comprises or "comprising", will be understood to imply the inclusion of a stated element integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps. The ter pharmaceuicaly acceptable salts' refers to salts comprise but not limited to wich are prepared from pha raceutically acceptable non-toxic aids, including inorganic ad organic acids, Suitable notxic acidsincude inorganic and organic acids such as acetic, benzenesulfoni benzoic camphorsuifonic, citric, ethenesufonic formic, funarie, glucondc glutamic, hydrobromic, hydrochoric, isethionin lactic, maleic, mali, mandelie methane sulfonic, mucic, nitric pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toulenesulbnic acids and the like. Preferably, Desvenlafaxine is in the salt form. More preferably Desvenlafaxine salt is Benzoate, Succinate, glu tarate & palmitate. In another embodiment Desvenlafaxine Benzoate is in crystaline form o in amophous for ora mixture thereof. It is to be understood for the purpose of invention that Desvenlafaxine Benzoate ray be present in the form of solvates with 6B organic solvents like ethanol, isopropanol or hydrate like mtonohydrate, dihydrate or enantiomers. It is to be understood for the purpose of invention, Desvenifaxine Benzoate can be prepared by methods disclosed in Indian Patent Application no, 0761/ KOL/20E11 are hereby incorporated in its entirety. In another embodinent, Desveniafaxine Benzoate is in crystaline forn characterized by a powder Xray diffraction pattern having at least one peak at about 54, 1035, 166, 180, 192, 2332 0.2 degrees 20 substantially as depicted in Figure 1. In another embodiment, Desvenlafaxine Benzoate is in crystaline form characterized by a powder X-ray diffraction pattern having peaks at about 5.4, 10.75, 16.6, 18.0, 19.2, 23.32 25 0.2 degrees 20 substantially as depicted in Figure 1. In another embodimentDesvenlafaxine Benzate is in crystalline form characterized by a powder X-ray diffraction patten having peaks at about 54, 95, 10.7, 16. 16., 173, 180, 19, 20.4, 233,2 0.2 degrees 20 substartialy as depicted in figure WO 2012/140577 PCT/IB2012/051761 7 In another embodiment, Desvenlafaxine Benzoate is in crystalline form characterized by a powder X-ray diffraction pattern substantially in accordance with Figure 1. More preferably, Desvenlafaxine Benzoate is in crystalline form characterized by a powder X-ray diffraction pattern having peaks at about 5.4, 9.5, 10.7, 16.1, 16.6, 17.3, 5 18.0, 19.2, 20.4, 21.5, 23.3, 24.9, 28.3, 29.9 ± 0.2 degrees 20. Desvenlafaxine Benzoate has solubility in water of greater than 30mg/ml, preferably the aqueous solubility of the Desvenlafaxine Benzoate is at least about 50 mg/ml at 25" C, more preferably, the aqueous solubility of Desvenlafaxine Benzoate is about 60 mg/ml at 250 C. 10 Desvenlafaxine Succinate has solubility in water of greater than 30mg/ml, preferably the aqueous solubility of the Desvenlafaxine Succinate is about 35 mg/ml at 250 C. Desvenlafaxine used in pharmaceutical compositions of invention in an amount of which is safe, well tolerated in patients with acceptable adverse effect profiles and are those in common practice and known to person skilled in the art. 15 Desvenlafaxine used to treat or prevent central nervous system disorders including, but not limited to depression (including but not limited to major depressive disorder, bipolar disorder and dysthymia), fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive 20 compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, (including premature ejaculation), borderline personality disorder, chronic fatigue syndrome, incontinence (including fecal incontinence, overflow 25 incontinence, passive incontinence, reflex incontinence, stress urinary incontinence, urge incontinence, urinary exertional incontinence and urinary incontinence), pain (including but not limited to migraine, chronic back pain, phantom limb pain, central pain, neuropathic pain such as diabetic neuropathy, and postherpetic neuropathy), Shy Drager WO 20121140577 PCT/IB2012/051761 8 can also be used for preventing relapse or recurrence of depression; to treat cognitive impairment; for the inducement syndrome, Raynaud's syndrome, Parkinson's Disease, epilepsy, and others. Compounds and compositions of the present invention of cognitive enhancement in patient suffering from senile dementia, Alzheimer's disease, memory 5 loss, amnesia and amnesia syndrome; and in regimens for cessation of smoking or other tobacco uses. The dosage amount useful to treat, prevent, inhibit or alleviate each of the aforementioned conditions will vary with the severity of the condition to be treated and the route of administration. The dose and dose frequency will also vary according to age, body 10 weight, response and past medical history of the individual human patient. Dosage is described in terms of the free base and is adjusted accordingly for the pharmaceutically acceptable salts. In managing the patient, is generally preferred that the therapy be initiated at a lower dose and increased if necessary. Dosages for non-human patients can be adjusted accordingly by one skilled in the art. 15 A modified release pharmaceutical composition according to the invention comprises but is not limited to tablets (single layered tablets, multilayered tablets, mini tablets, bioadhesive tablets, caplets, matrix tablets, tablet within a tablet, mucoadhesive tablets, modified release tablets, pulsatile release tablets, and timed release tablets), pellets, beads, granules, sustained release formulations, capsules, microcapsules, tablets in capsules, 20 microspheres, matrix formulations, microencapsulation. The term "modified release" used in pharmaceutical compositions of invention means controlled release, extended release, sustained release, delayed release or combination of any of these techniques. In other words, modified release pharmaceutical composition of inventions may be any formulation technique wherein release of the active substance 25 from the composition is modified to occur at a slower rate than that from an immediate release composition.

WO 2012/140577 PCT/IB2012/051761 9 In one embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof. In another embodiment, a modified release pharmaceutical composition comprising 5 Desvenlafaxine Succinate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipients(s) thereof. In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof. 10 In another embodiment, a modified release pharmaceutical composition comprising crystalline form of Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof. In another embodiment, a modified release pharmaceutical composition comprising crystalline form of Desvenlafaxine Benzoate characterized by a powder X-ray diffraction 15 pattern having at least one peak at about 5.4, 10.75, 16.6, 18.0, 19.2, 23.32 ± 0.2 degrees 20 substantially as depicted in Figure 1, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof. In another embodiment, a modified release pharmaceutical composition comprising crystalline form of Desvenlafaxine Benzoate characterized by a powder X-ray diffraction 20 pattern having peak at about 5.4, 10.75, 16.6, 18.0, 19.2, 23.32 ± 0.2 degrees 20 substantially as depicted in Figure 1, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof. In another embodiment, a modified release pharmaceutical composition comprising crystalline form of Desvenlafaxine Benzoate characterized by a powder X-ray diffraction 25 pattern having peaks at about 5.4, 9.5, 10.75, 16.1, 16.6, 17.3, 18.0, 19.2, 20.4, 23.32 ± 0.2 degrees 20 substantially as depicted in Figure 1, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.

WO 20121140577 PCT/IB2012/051761 10 In another embodiment, a modified release pharmaceutical composition comprising crystalline form of Desvenlafaxine Benzoate characterized by a powder X-ray diffraction pattern substantially in accordance with Figure 1, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof. 5 In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate in crystalline form characterized by a powder X-ray diffraction pattern having peaks at about 5.4, 9.5, 10.7, 16.1, 16.6, 17.3, 18.0, 19.2, 20.4, 21.5, 23.3, 24.9, 28.3, 29.9 ± 0.2 degrees 20, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof. 10 In another embodiment, a modified release pharmaceutical composition comprising amorphous form of Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof. In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine glutarate, one or more release modifying agent(s) and one or more 15 pharmaceutically acceptable excipient(s) thereof. In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine palmitate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof. The release modifying agent(s) is hydrophilic, hydrophobic or combinations thereof. 20 In another embodiment, a modified release pharmaceutical composition comprises Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof wherein release modifying agent(s) is from about I % to about 95 % based on total weight of composition. In another embodiment, a modified release pharmaceutical composition comprises 25 Desvenlafaxine Succinate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof wherein release modifying agent(s) is present in an amount less than about 55% based on total weight of composition.

WO 20121140577 PCT/IB2012/051761 11 In another embodiment, a modified release pharmaceutical composition comprises Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof wherein release modifying agent(s) is from about 1 % to about 95 % based on total weight of composition. 5 The hydrophilic release modifying agent(s) according to invention comprises but not limited cellulose derivatives, alginic acid derivatives, polysaccharides, alkylene oxides or mixtures thereof. Preferably, hydrophilic release modifying agent(s) comprises celluloses or their salts or derivatives thereof, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl 10 methylcellulose (hypromellose), sodium carboxymethyl cellulose, alginic acid or their salts and derivatives thereof, carbomer (Carbopol(TM)), polyethyleneoxide, xanthan gum, guar gum, locust bean gum, poly vinyl acetate, polyvinyl alcohol, lactose. The hydrophobic release modifying agent(s) according to the invention comprises but not limited to hydrogenated vegetable oils, polymethacrylates, ethyl cellulose or mixtures 15 thereof. Preferably, hydrophobic release modifying agent(s) comprises Ammonio methacrylate copolymers type A and B as described in USP, methacrylic acid copolymer type A, B and C as described in USP, Polyacrylate dispersion 30% as described in Ph. Eur., Polyvinyl acetate dispersion, ethylcellulose, cellulose acetate, cellulose propionate (lower, medium 20 or higher molecular weight), cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, poly(methyl methacrylate), poly(ethyl methacrylate), poly(butyl methacrylate), poly(isobutyl methacrylate), and poly(hexyl methacrylate). Poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl actylate), 25 poly(octadecyl acrylate), waxes such as beeswax, carnauba wax, microcrystalline wax, and ozokerite; fatty alcohols such as cetostearyl alcohol, stearyl alcohol; cetyl alcohol and myristyl alcohol; and fatty acid esters such as glyceryl monostearate, glycerol distearate; glycerol monooleate, acetylated monoglycerides, tristearin, tripalmitin, cetyl esters wax, glyceryl palmitostearate, glyceryl behenate, and hydrogenated castor oil.

WO 20121140577 PCT/IB2012/051761 12 The average particle size of the particles of Desvenlafaxine or a pharmaceutically acceptable salt thereof, in the modified release pharmaceutical composition of the invention is between about 5 microns to about 120 microns, preferably between about 7 5 microns to about 100 microns and more preferably about 10 microns to about 80 microns. The terms "average particle size", "dso" and "mass mean diameter" can be used interchangeably. The average particle size, i.e. the average equivalent diameter, is defined as the diameter where 50 mass % of the particles of the Desvenlafaxine have a larger equivalent diameter, 10 and the other 50 mass-% have a smaller equivalent diameter. The "average particle size" also refers to the median particle diameter based on mass (i.e. the particle diameter where one half of the mass of particles is contributed by particles with a lesser diameter and one half of the mass of particles is contributed by particles with a greater diameter). 15 'the particle size can be measured using various commonly available methods such as measurement using light (eg. light-scattering methods or turbidimetric methods), sedimentation methods (eg. pipette analysis using an Andreassen pipette, sedimentation scales, photo-sedimentometers or sedimentation in a centrifugal force), pulse methods (eg. Coulter counter), or sorting by means of gravitational or centrifugal force. 20 It is to be understood for the purpose determining particle size of Desvenlafaxine or pharmaceutically acceptable salts like Succinate or Benzoate in pharmaceutical compositions, the methods comprising but not limited to isolating, crushing, extracting, separating and precipitating can be commonly employed. Determining particle size of Desvenlafaxine or pharmaceutically acceptable salts like Succinate or Benzoate in 25 pharmaceutical compositions is well within the scope of present invention. In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Blenzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein d% 0 particle size of Desvenlafaxine is upto about 80 microns.

WO 20121140577 PCT/IB2012/051761 13 In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein d 50 particle size of Desvenlafaxine Benzoate is from about 10 microns to about 80 microns. 5 In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Succinate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein d 5 o particle size of Desvenlafaxine Succinate is upto about 80 microns. In another embodiment, a modified release pharmaceutical composition comprising 10 Desvenlafaxine Succinate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein d 50 particle size of Desvenlafaxine Succinate is upto about 50 microns. In another embodiment, a modified release pharmaceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one 15 or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s). In another embodiment, a modified release pharmaceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one 20 or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), such that d 50 particle size of Desvenlafaxine is upto about 80 microns. In another embodiment, a modified release pharmaceutical composition comprises a 25 matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more pharmaceutically WO 20121140577 PCT/IB2012/051761 14 acceptable excipient(s), wherein release of Desvenlafaxine is predominantly modified by coating. In another embodiment, a modified release pharmaceutical composition having release of Desvenlafaxine in two or more steps at different release rates, which comprises a) a 5 modified release part A comprising Desvenlafaxine, one or more release modifying agents) and one or more pharmaceutically acceptable excipient(s) and b) a modified release part B comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s). In another embodiment, a modified release pharmaceutical composition having release of 10 Desvenlafaxine in two or more steps at different release rates, which comprises a) a modified release part A comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) and b) a modified release part B comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein part A is coated with part 15 B. In another embodiment, a modified release pharmaceutical composition is bi-layer tablet comprises a sustained release layer comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s); and immediate release layer comprising Desvenlafaxine and one or more pharmaceutically 20 acceptable excipient(s). In another embodiment, a modified release pharmaceutical composition is multi-layered tablet. In another embodiment, a modified release pharmaceutical composition comprises a inert core which is loaded with drug layer comprising Desvenlafaxine Benzoate, one or more 25 release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein Desvenlafaxine Benzoate layer being further coated with one or more release modifying layer comprising release modifying agent(s) and one or more pharmaceutically acceptable excipient(s). In another embodiment, a modified release pharmaceutical composition comprises a inert 30 core which is loaded with drug layer comprising Desvenlafaxine Succinate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) WO 20121140577 PCT/IB2012/051761 15 wherein Desvenlafaxine Succinate layer being further coated with one or more release modifying layer comprising release modifying agent(s) and one or more pharmaceutically acceptable excipient(s). The inert core comprises but not limited to sugar sphere or pellets, microcrystalline 5 cellulose sphere, sugar/starch core or any suitable material. In another embodiment drug layer and release modifying layer may be separated by one or more separating layers. The separating layer comprises one or more pharmaceutically acceptable excipients and one or more hydrophilic agent(s), hydrophobic agent(s) or combination thereof. 10 The hydrophilic agent(s) according to invention comprises but not limited to cellulose derivatives, alginic acid derivatives, polysaccharides, alkylene oxides or mixtures thereof. Preferably, hydrophilic agent(s) comprises celluloses or their salts or derivatives thereof, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (hypromellose), sodium carboxymethyl cellulose, alginic acid or their salts and 15 derivatives thereof, carbomer (Carbopol(TM)), polyethyleneoxide, xanthan gum, guar gum, locust bean gum, poly vinyl acetate, polyvinyl alcohol, lactose. The hydrophobic agent(s) according to the invention comprises but not limited to hydrogenated vegetable oils, polymethacrylates, ethyl cellulose or mixtures thereof. Preferably, hydrophobic agent(s) comprises Ammonio methacrylate copolymers type A 20 and B as described in USP, methacrylic acid copolymer type A, B and C as described in USP, Polyacrylate dispersion 30% as described in Ph. Eur., Polyvinyl acetate dispersion, ethylcellulose, cellulose acetate, cellulose propionate (lower, medium or higher molecular weight), cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, poly(methyl methacrylate), poly(ethyl methacrylate), 25 poly(butyl methacrylate), poly(isobutyl methacrylate), and poly(hexyl methacrylate). Poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl actylate), poly(octadecyl acrylate), waxes such as beeswax, carnauba wax, microcrystalline wax, and ozokerite; fatty alcohols such as cetostearyl alcohol, stearyl alcohol; cetyl alcohol and myristyl WO 20121140577 PCT/IB2012/051761 16 alcohol; and fatty acid esters such as glyceryl monostearate, glycerol distearate; glycerol monooleate, acetylated monoglycerides, tristearin, tripalmitin, cetyl esters wax, glyceryl palmitostearate, glyceryl behenate, and hydrogenated castor oil. The term 'pharmaceutically acceptable excipient(s)' used in pharmaceutical compositions 5 of invention comprise but not limited to diluents, binders, pH stabilizing agents, disintegrants, surfactants, glidants and lubricants. The amounts of excipient(s) employed will depend upon how much active agent is to be used. One excipient(s) can perform more than one function. Binders as used in the invention comprises but are not limited to, starches such as potato 10 starch, wheat starch, corn starch; microcrystalline cellulose such as products known under the registered trademarks Avicel, Filtrak, Heweten or Pharmacel; celluloses such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose (HPMC), ethyl cellulose, sodium carboxy methyl cellulose; natural gums like acacia, alginic acid, guar gum; liquid glucose, dextrin, povidone, syrup, polyethylene oxide, 15 polyvinyl pyrrolidone, poly-N-vinyl amide, polyethylene glycol, gelatin, poly propylene glycol, tragacanth, combinations thereof and other materials known to one of ordinary skill in the art and mixtures thereof. Fillers or diluents, as used in the invention comprises but not limited to confectioner's sugar, compressible sugar, dextrates, dextrin, dextrose, fructose, lactitol, mannitol, 20 sucrose, starch, lactose, xylitol, sorbitol, talc, microcrystalline cellulose, calcium carbonate, calcium phosphate dibasic or tribasic, calcium sulphate, and the like can be used. Lubricants as used in the invention comprises but not limited to Mg, Al ,Ca or Zn stearate, polyethylene glycol, glyceryl behenate, mineral oil, sodium stearyl fumarate, 25 stearic acid, hydrogenated vegetable oil and talc. Glidants comprises but not limited to, silicon dioxide; magnesium trisilicate, powdered cellulose, starch, talc and tribasic calcium phosphate, calcium silicate, magnesium silicate, colloidal silicon dioxide, silicon hydrogel and other materials known to one of ordinary skill in the art.

WO 20121140577 PCT/IB2012/051761 17 Disintegrants comprises but not limited to starches; clays; celluloses; alginates; gums; cross-linked polymers, e.g., cross-linked polyvinyl pyrrolidone or crospovidone, e.g., POLYPLASDONE XL, cross-linked sodium carboxymethylcellulose or croscarmellose sodium, e.g., AC-DI-SOL from FMC; and cross-linked calcium carboxymethylcellulose; 5 soy polysaccharides; and guar gum. Use of disintegrant according to the invention facilitates in the release of drug in the latter stage and thereby completely releasing the drug from the dosage form. The pharmaceutical composition may optionally contain a surface-active agent. The preferred agent is copolymers composed of a central hydrophobic chain of 10 polyoxypropylene (poly (propylene oxide)) and polyoxyethylene (poly (ethylene oxide)) that is well known as poloxamer. However, other agents may also be employed such as dioctyl sodium sulfosuccinate (DSS), triethanolamine, sodium lauryl sulphate (SLS), polyoxyethylene sorbitan and poloxalkol derivatives, quaternary ammonium salts or other pharmaceutically acceptable surface-active agents known to one ordinary skilled in the 15 art. The pharmaceutical composition can be formed by various processes known in the art but not limited to such as by dry granulation, wet granulation, melt granulation, direct compression, double compression, extrusion spheronization, layering and the like. The solvent(s) used in wet granulation include all the solvents well known in the art or the 20 mixtures thereof. In another embodiment, a modified pharmaceutical composition of invention comprises one or more coating comprising but not limited to modified release coating, sustained release coating, extended release coating, enteric coating, partial enteric coating or leaky enteric coating, bioadhesive coating and similar coatings known in the art. These 25 coatings may help the pharmaceutical composition to release the drug at and for the required time. These coatings comprise coating agent(s) selected from hydrophilic or hydrophobic agent(s) or the combinations thereof. The hydrophobic agent(s) in the coating comprises but not limited to Ammonio 30 methacrylate copolymers type A and B as described in USP, methacrylic acid copolymer WO 20121140577 PCT/IB2012/051761 18 type A, B and C as described in USP, Polyacrylate dispersion 30% as described in pH. Eur., Polyvinyl acetate dispersion, ethylcellulose, cellulose acetate, cellulose propionate (lower, medium or higher molecular weight), cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, poly(methyl 5 methacrylate), poly(ethyl methacrylate), poly(butyl methacrylate), poly(isobutyl methacrylate), and poly(hexyl methacrylate). Poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl actylate), poly(octadecyl acrylate), waxes such as beeswax, carnauba wax, microcrystalline wax, and ozokerite; fatty alcohols such as cetostearyl alcohol, stearyl 10 alcohol; cetyl alcohol and myristyl alcohol; and fatty acid esters such as glyceryl monostearate, glycerol distearate; glycerol monooleate, acetylated monoglycerides, tristearin, tripalmitin, cetyl esters wax, glyceryl palmitostearate, glyceryl behenate, and hydrogenated castor oil. The hydrophilic agent(s) in the coating comprises but not limited to celluloses or their 15 salts or derivatives thereof, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (hypromellose), sodium carboxymethyl cellulose, alginic acid or their salts and derivatives thereof, carboiner (Carbopol(TM)), polyethyleneoxide, xanthan gum, guar gum, locust bean gum, poly vinyl acetate, polyvinyl alcohol, lactose, PVA these hydrophilic polymers also act as pore forming agent. 20 These coating comprises one or more excipients selected from the group comprising coating agents, opacifiers, taste-masking agents, fillers, polishing agents, colouring agents, antitacking agents and the like. The pharmaceutical composition can be coated by a wide variety of methods. Suitable methods include compression coating, coating in a fluidized bed or a pan and hot melt 25 (extrusion) coating. Such methods are well known to those skilled in the art. In another embodiment, a stable modified release pharmaceutical composition comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.

WO 20121140577 PCT/IB2012/051761 19 In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein composition releases about 75% of Desvenlafaxine in 16 hours measured using UTSP Type I dissolution apparatus in 900 ml 5 of 0.9% NaCl in water at 100 rpm. In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Succinate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein composition releases about 75% of Desvenlafaxine Succinate in 16 hours measured using USP Type I dissolution apparatus 10 in 900 ml of 0.9% NaCl in water at 100 rpm. In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein d% 0 particle size of Desvenlafaxine is upto about 80 microns such that composition releases about 75% of Desvenlafaxine in 16 15 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm. In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein d 50 particle size of Desvenlafaxine 20 Benzoate is from about 5 microns to about 80 microns such that composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm. In another embodiment, a modified release pharmaceutical composition comprises from about 10 % to about 50% by weight of Desvenlafaxine Succinate and less than about 60 25 % of release modifying agent(s) based upon total weight of composition, wherein d 5 0 particle size of Desvenlafaxine Succinate is upto about 50 microns such that composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm. In another embodiment, a modified release pharmaceutical composition comprises a 30 matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further WO 20121140577 PCT/IB2012/051761 20 coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCI in water at 100 rpm. 5 In another embodiment, a modified release pharmaceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein d 50 particle size of Desvenlafaxine is upto about 80 10 microns such that composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm. In another embodiment of the invention is a method of lowering the incidence of nauseau, vomiting, diarrhea, abdominal pain, headache, vaso-vagal malaise, and/or trismus 15 resulting from the oral administration of venlafaxine, Desvenlafaxine, or a salt of Desvenlafaxine other than Desvenlafaxine Benzoate to a patient. The method includes orally administering to a patient in need thereof a therapeutically effective amount of Desvenlafaxine Benzoate. In another embodiment of the invention is a method of lowering the incidence of nausea, 20 vomiting, diarrhea, abdominal pain, headache, vaso-vagal malaise, and/or trismus resulting from the oral administration of Desvenlafaxine Benzoate to a patient. The method includes orally administering to a patient in need thereof a therapeutically effective amount of a sustained release oral dosage form comprising Desvenlafaxine Benzoate having a peak blood plasma level of less than about 225 ng/ml. 25 Desvenlafaxine Benzoate may also be provided in combination with venlafaxine. The dosage of venlafaxine is preferably about 75 mg to about 350 mg/day and more preferably about 75 img to about 225 mg/day. Still more preferably the dosage of venlafaxine is about 75 mg to about 150 mg/day. The ratio of Desvenlafaxine to WO 20121140577 PCT/IB2012/051761 21 venlafaxine will vary from patient to patient depending upon a patient's response rate, but generally will be at least 6:1 Desvenlafaxine to venlafaxine. Desvenlafaxine Benzoate is less fluffy than that of Desvenlafaxine Succinate. So, the dusting is less during manufacturing of the drug product and which gives ease of handling 5 the drug substance as compared to the Succinate and there is a minimum chance of drug loss during manufacturing process and hence gives an advantage over Succinate salt. Further, the particle size distribution of Desvenlafaxine Benzoate drug substance is smaller as compared to Desvenlafaxine Succinate drug substance. Hence, the distribution of drug substance in the drug product is uniform and gives no chance of variation in 10 content uniformity of the final drug product/dosage form. Due to its advantegeous properties, lower concentration of rate controlling polymers or release modifying polymers is required for Desvenlafaxine Benzoate as compared to Desvenlafaxine Succinate in matrix tablet formulation to achieve the similar drug release profile and also to make the bioequivalent product with Pristiq. 15 Pristiq*" is the brandname for the extended release composition of Desvenlafaxine Succinate, 50 mg and 100 mg marketed by Wyeth Pharmaceuticals Inc. (Now Pfizer) Philadelphia, PA 19101. In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more 20 pharmaceutically acceptable excipient(s), wherein the modified release composition provides Cm., (peak plasma levels) of upto about 225 ng/ml. In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein the modified release composition 25 provides Cm. (peak plasma levels) of upto about 300 ng/ml. In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof, wherein Cma and AUC of the modified WO 20121140577 PCT/IB2012/051761 22 release composition are within the limit of 80 % to 125 % of Cmax and AUC of the extended release composition of Desvenlafaxinc Succinate. The term "Cma" as used herein, means maximum plasma concentration of Desvenlafaxine produced by the ingestion of the modified release composition of 5 invention or the marketed Pristiq® (Extended Release Composition of Desvenlafaxine Succinate) composition. Cmax or peak plasma level may be used interchangeably. The term "AUC" as used herein, means area under the plasma concentration-time curve of Desvenlafaxine produced by the ingestion of the modified release composition of invention or the marketed Pristiq® (Extended Release Composition of Desvenlafaxine 10 Succinate). In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof wherein, Tmax of the modified release composition is comparable to Tmx of the extended release composition of Desvenlafaxine 15 Succinate. The term "Tmax" as used herein, means time to the maximum observed plasma concentration of Desvenlafaxine produced by the ingestion of the modified release composition of invention or the marketed Pristiq® (Extended Release Composition of Desvenlafaxine Succinate). 20 In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof wherein, Tmax of the modified release composition is less than about 8 hours. In another embodiment, Cm and AUC were comparable for the modified release 25 composition of Desvenlafaxine Benzoate when administered after a high-fat meal and under fasting condition as the ratios falls between 80-125%.

WO 20121140577 PCT/IB2012/051761 23 In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agents) and one or more pharmaceutically acceptable excipient(s) thereof wherein C.,,,, and AUC of the modified release composition are independent of food effect. 5 In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof, which is bioequivalent to Pristiq@ tablet in a bioavailability study in humans. A modified release pharmaceutical composition of the present invention can be used to 10 treat or prevent central nervous system disorders including, but not limited to depression (including but not limited to major depressive disorder, bipolar disorder and dysthymia), fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including 15 trichotillomania), social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, (including premature ejaculation), borderline personality disorder, chronic fatigue syndrome, incontinence (including fecal incontinence, overflow incontinence, passive 20 incontinence, reflex incontinence, stress urinary incontinence, urge incontinence, urinary exertional incontinence and urinary incontinence), pain (including but not limited to migraine, chronic back pain, phantom limb pain, central pain, neuropathic pain such as diabetic neuropathy, and postherpetic neuropathy), Shy Drager can also be used for preventing relapse or recurrence of depression to treat cognitive impairment; for the 25 inducement syndrome, Raynaud's syndrome, Parkinson's Disease, epilepsy, and others. Compounds and compositions of the present invention of cognitive enhancement in patient suffering from senile dementia, Alzheimer's disease, memory loss, amnesia and amnesia syndrome; and in regimens for cessation of smoking or other tobacco uses. Additionally, compounds and compositions of the present invention can be used for 30 treating hypothalamic amenorrhea in depressed and non-depressed human females.

WO 20121140577 PCT/IB2012/051761 24 The following examples are illustrative of the present invention, and the examples should not be considered as limiting the scope of this invention in any way, as these examples and other equivalents thereof will become apparent to those versed in the art, in the light of the present disclosure, and the accompanying claims. 5 X -RD Stability Study The X-ray diffraction pattern for Desvenlafaxine Benzoate was measured using X-ray diffractometer. X-RD pattern for Desvenlafaxine Benzoate is depicted in Figure 1. 10 Example 1: WO 20121140577 PCT/IB2012/051761 25 S.NO. NAME OF INGREDIENTS % W/W Intragranular 1 Desvenlafaxine Benzoate 36.58 2 Hypromellose 31.7 3 Povidone 6.10 4 Purified Water USP/ IPA q.s Dibasic calcium phosphate / 18.12 Microcrystalline Cellulose NF Extragranular 6 Aerosil 3.0@0 7 Magnesium Stearate/Stearic Acid 2.00 Film Coating 8 Opadrly 2.50 9 Purified Water USP/ IPA/DCM q.s 15 Procedure: 1. Aqueous/Non-aqueous granulation of Desvenlafaxine Benzoate, Hypromellose and Dibasic calcium phosphate/ MCC using Povidone as binder. 2. Dry the granules at 50±5'C till desired LOD is achieved. 20 3. Add the Extragranular part and mix well. 4. Compress the granules using suitable punch tooling 5. Aqueous /Non-aqueous film coating. 25 WO 20121140577 PCT/IB2012/051761 26 Example 2: S.NO. NAME OF INGREDIENTS % W/W Intragranular I Desvenlafaxine Benzoate 36.58 5 2 lypromellose 20.00 3 Povidone 6.10 4 Purified Water/IPA qs 5 Dibasic calcium phosphate/ Microcrystalline Cellulose 17.82 Extragranular 10 6 Aerosil 3.00 7 Magnesium Stearate/Stearic Acid 2.00 Release Modifying Coating 9 Ilypromellose 7.00 10 Ethyl cellulose 5.00 11 IPA/DCM q.s 15 Film Coating 12 Opadry 2.50 13 Purified Water USP/ IPA/DCM qs Procedure: 20 1. Aqueous /Non-aqueous granulation of Desvenlafaxine Benzoate, Hypromellose and Dibasic calcium phosphate/ MCC using Povidone as binder. 2. Dry the granules at 50±5 0 C till desired LOD is achieved. 3. Add the Extragranular part and mix well. 4. Compress the granules using suitable punch tooling 25 5. Non- Aqueous coating with a build up of 1-10%w/w. 6. Aqueous /Non-aqueous film coating.

WO 20121140577 PCT/IB2012/051761 27 Example 3: S.NO NAME OF INGREDIENT % W/W Intragranular 1 Desvenlafaxine Glutarate/Palmitate 36.58 2 Hypromellose 18.30 3 Povidone 6.10 4 Microcrystalline Cellulose / Dibasic calcium phosphate 13.22 5 Purified Water q.s Extragranular 6 Hypromellose 18.30 7 Colloidal Silicon Dioxide 3.00 8 Stearic acid 2.00 Film Coating 9 Opadry 2.50 10 Purified Water USP/ IPA/DCM q.s Procedure: 5 1. Aqueous /Non-aqueous granulation of Desvenlafaxine Glutarate/Palmitate, Hypromellose and Dibasic calcium phosphate / MCC using Povidone as binder. 2. Dry the granules at 50±5"C till desired LOD is achieved. 3. Add the Extragranular part and mix well. 4. Compress the granules using suitable punch tooling. 10 5. Aqueous /Non-aqueous film coating.

WO 20121140577 PCT/IB2012/051761 28 Example 4: S.NO NAME OF INGREDIENT % W/W Immediate release layer 1 Desvenlafaxine Benzoate 4.87 2 Povidone 4.87 3 Purified Water 4 Dibasic calcium phosphate / Microcrystalline 11.50 Cellulose 5 Colloidal Silicon Dioxide 1.00 6 Magnesium Stearate 1.00 Sustained release layer 7 Desvenlafaxine Benzoate 31.70 8 Eudragit or Ethylcellulose 25.00 9 Purified Water q.s 10 Dibasic calcium phosphate / Microcrystalline 13.56 Cellulose 11 Colloidal Silicon Dioxide 2.00 12 Magnesium stearate 2.00 Film Coating 13 Opadry 2.50 14 Purified Water USP/ IPA/DCM q.s Procedure: Immediate release layer 5 1. Aqueous /Non-aqueous granulation of Desvenlafaxine Benzoate and Dibasic calcium phosphate/ MCC using Povidone as binder.

WO 20121140577 PCT/IB2012/051761 29 2. Dry the granules at 50±5'C till desired LOD is achieved. 3. Add Colloidal Silicon Dioxide and Magnesium stearate and mix well. Sustained release layer 1. Aqueous/Non-aqueous granulation of Desvenlafaxine Benzoate, Dibasic calcium 5 phosphate / MCC using Methacrylic acid or Ethylcellulose as sustained release polymer. 2. Dry the granules at 50±5'C till desired LOD is achieved 3. Add Colloidal Silicon Dioxide and Magnesium stearate and mix well. 4. Compress both the layers of Immediate and Sustained release part using suitable punch tooling. 10 5. Aqueous /Non-aqueous film coating. Example 5: S.NO. NAME OF INGREDIENT % W/W 1 Desvenlafaxine Succinate 36.58 2 Hypromellose / Xanthan gum 40.00 3 Microcrystalline Cellulose / Dibasic calcium phosphate 15.92 4 Colloidal Silicon Dioxide 3.00 5 Stearic acid / Magnesium Stearate 2.00 Film Coating 6 Opadry 2.50 Purified Water USP/ IPA/DCM qs Procedure: 15 1. Desvenlafaxine Succinate and Hypromellose or Xanthum gum are dry mixed. 2. Add Microcrystalline Cellulose / Dibasic calcium phosphate to step I and mix well. 3. Add Colloidal Silicon Dioxide to Step 3 and mix well. 4. Lubricate the blend with Stearic acid or Magnesium Stearate.

WO 20121140577 PCT/IB2012/051761 30 5. Compress the granules using suitable punch tooling. 6. Aqueous /Non-aqueous film coating. Example 6: 5 S.NO. NAME OF INGREDIENTS % W/W Intragranular 1 Desvenlafaxine Succinate 36.58 2 Hypromellose 20.00 3 Povidone 6.100 4 Purified Water/IPA qs Dibasic calcium phosphate/ 17.82 Microcrystalline Cellulose Extragranular 6 Aerosil 3.00 7 Magnesium Stearate/Stearic Acid 2.00 Release Modifying Coating 15 9 Hypromellose 7.00 10 Ethyl cellulose 5.00 11 IPA/DCM q.s Film Coating 12 Opadry 2.50 13 Purified Water USP/ IPA/DCM qs 20 Procedure: WO 20121140577 PCT/IB2012/051761 31 1. Aqueous /Non-aqueous granulation of Desvenlafaxine Succinate, Hypromellose and Dibasic calcium phosphate/ MCC using Povidone as binder. 2. Dry the granules at 50±5 0 C till desired LOD is achieved. 3. Add the Extragranular part and mix well. 5 4. Compress the granules using suitable punch tooling 5. Non- Aqueous coating with a build up of 1-10%w/w. 6. Aqueous /Non-aqueous film coating. Example 7: S.NO NAME OF INGREDIENT % W/W Part-A 1 Desvenlafaxine Succinate 4.87 2 Povidone 4.87 3 Purified Water 4 Dibasic calcium phosphate / Microcrystalline 11.50 Cellulose 5 Colloidal Silicon Dioxide 1.00 6 Magnesium Stearate 1.00 Part-B 7 Desvenlafaxine Succinate 31.70 8 Eudragit or Ethylcellulose 25.00 9 Purified Water q.s 10 Dibasic calcium phosphate / Microcrystalline 13.56 Cellulose 11 Colloidal Silicon Dioxide 2.00 WO 20121140577 PCT/IB2012/051761 32 12 Magnesium stearate 2.00 Film Coating 13 Opadry 2.50 14 Purified Water ITSP/ IPA/DCM q.s Procedure: Part A 1. Aqueous /Non-aqueous granulation of Desvenlafaxine Succinate and Dibasic 5 calcium phosphate/ MCC using Povidone as binder. 2. Dry the granules at 50±5 0 C till desired LOD is achieved. 3. Add Colloidal Silicon Dioxide and Magnesium stearate and mix well. Part B 4. Aqueous /Non-aqueous granulation of Desvenlafaxine Succinate, Dibasic calcium 10 phosphate / MCC using Methacrylic acid or Ethylcellulose as sustained release polymer. 5. Dry the granules at 50±5'C till desired LOD is achieved 6. Add Colloidal Silicon Dioxide and Magnesium stearate and mix well. 7. Compress both the layers of Part A and Part B part using suitable punch tooling. 15 8. Aqueous /Non-aqueous film coating. Example 8: S.NO. NAME OF INGREDIENT % W/W 1 Desvenlafaxine Succinate 36.58 2 Ethyl Cellulose 40.00 3 Microcrystalline Cellulose / Dibasic calcium phosphate 15.92 4 Colloidal Silicon Dioxide 3.00 5 Stearic acid / Magnesium Stearate 2.00 WO 20121140577 PCT/IB2012/051761 33 Film Coating 6 Opadry 2.50 Purified Water ISP/ IPA/DCM q.s Procedure: 1. Desvenlafaxine Succinate and Ethyl Cellulose are dry mixed. 2. Add Microcrystalline Cellulose / Dibasic calcium phosphate to step 1 and mix well. 3. Add Colloidal Silicon Dioxide to Step 3 and mix well. 5 4. Lubricate the blend with Stearic acid or Magnesium Stearate. 5. Compress the granules using suitable punch tooling. 6. Aqueous /Non-aqueous film coating. Example 9: S.NO NAME OF INGREDIENT % W/W Sugar Hardening 1 Sugar sphere 98.00 2 HPMC 2.00 3 DCM/IPA Qs Total 100.00 Drug Loading 4 Sugar spheres 40.00 5 Desvenlafaxine Succinate 42.00 6 HPMC 2.75 7 Talc 5.00 8 Aerosil 5.00 WO 20121140577 PCT/IB2012/051761 34 9 Glyceryl monostearate 5.00 10 IPA/DCM q.s 11 Total wt. 100.00 Release Modifying coating 12 HPMC 16.00 13 Ethyl cellulose 48.00 14 Triethyl citrate 16.00 15 Talc 16.00 16 DCM:lPA q.s Total 100.00 Procedure 1. Hardening of sugar spheres carried out. 2. Mix Desvenlafaxine Succinate, HPMC, talc & Aerosil. 5 3. Coat the mixture of Step 2 on sugar spheres of step 1 using DCM/IPA solution to form drug layer. 4. Release Modifying coating of HPMC, ethyl cellulose, talc and triethyl citrate loaded on Drug layer of Step 3. 10 Example 10: Ingredients %w/w Intragranular 1 Desvenlafaxine Benzoate 36.52 2 Hypromellose 40.24 3 Povidone 4.88 4 Isopropyl Alcohol q.s WO 20121140577 PCT/IB2012/051761 35 Extragranular 5 Microcrystalline Cellulose 8.36 6 Colloidal Silicon Dioxide 3.66 7 Talc 1.95 8 Stearic Acid 1.95 Film Coating 9 Opadry 2.44 10 Purified water q.s Procedure: 1. Non-aqueous granulation of Desvenlafaxine Benzoate and Hypromellose using Povidone as binder. 5 2. Dry the granules at 55±5'C till desired LOD is achieved. 3. Add the Extragranular part and mix well. 4. Compress the granules using suitable punch tooling 5. Aqueous film coating. 10 Example 11: ngredients %w/w Intragranular 1 Desvenlafaxine 37.26 Succinate 2 Hypromellose 46.34 3 Povidone 4.88 4 Isopropyl Alcohol q.s Extragranular 5 Microcrystalline 1.52 Cellulose 6 Colloidal Silicon 3.66 WO 20121140577 PCT/IB2012/051761 36 Dioxide 7 Talc 1.95 8 Stearic Acid 1.95 Film Coating 9 Opadry 2.44 10 Purified water q.s Procedure: 1. Non-aqueous granulation of Desvenlafaxine Succinate and Hypromellose using Povidone as binder. 5 2. Dry the granules at 55±5'C till desired LOD is achieved. 3. Add the Extra granular part and mix well. 4. Compress the granules using suitable punch tooling 5. Aqueous film coating. 10 Example 12: ngredients %w/w Intragranular 1 Desvenlafaxine 36.24 Succinate 2 Hypromellose 43.0 -57.0 3 Colloidal Silicon Dioxide 0.5-2.0 4 Tale 0.5-2.0 5 Magnesium Stearate 0.5-2.0 Extragranular 6 Microcrystalline 3.0-5.76 Cellulose WO 20121140577 PCT/IB2012/051761 37 7 Colloidal Silicon 0.5-2.0 Dioxide 8 Tale 0.5-2.0 9 Magnesium Stearate 0.5-2.0 Fihn Coating 10 Opadry 2.0-3.0 11 Purified water q.s Procedure: 1. Compact Desvenlafaxine Succinate, Ilypromellose, Colloidal Silicon Dioxide, Talc and Magnesium Stearate in a roller compactor. 5 2. Sift and size the granules using comminuting mill to desired granules size. 3. Add the Extragranular part and mix well. 4. Compress the granules using suitable punch tooling 5. Aqueous film coating. 10 Example 13: ingredients %w/w Intragranular 1 Desvenlafaxine 37.56 Benzoate 2 Hypromellose 0.00-53.00 3 Tale 0.5-2.0 4 Stearic Acid 0.5-2.0. Extragranular 5 Microcrystalline 5.00-16.44 Cellulose 6 Colloidal Silicon 0.5-5.0 Dioxide WO 20121140577 PCT/IB2012/051761 38 7 Tale 0.5-2.0 8 Stearic Acid 0.5-2.0 Film Coating 9 Opadry 1.94-3.0 10 Purified water q.s Procedure: 1. Compact Desvenlafaxine Benzoate, Hypromellose, Tale and Stearic Acid in a roller compactor. 5 2. Sift the granules using comminuting mill to desired granules size. 3. Add the Extragranular part and mix well. 4. Compress the granules using suitable punch tooling 5. Aqueous film coating. In-Vitro Dissolution Study: 10 Table 1 given below shows the dissolution profile of Desvenlafaxine Benzoate Modified Release Tablets of Example 1 of the present invention carried out in 900 ml of 0.9% NaCt in water for 24 hours using Apparatus USP-I (Basket) at 100 rpm speed. The release profile (cumulative % of drug released) is given in Table 1. Table 1: Time In Cumulative % Drug Hrs Release For Example 1 1 Not More [han 20% 4 30-50% 8 50-70% 16 Not Less Than 75% WO 20121140577 PCT/IB2012/051761 39 Table 2 given below shows the dissolution profile of Desvenlafaxine Succinate Modified Release Tablets of Example 5 of the present invention carried out in 900 ml of 0.9% NaCl in water for 24 hours using Apparatus USP-I (Basket) at 100 rpm speed. The release profile (cumulative % of drug released) is given in Table 1. 5 Table 2: Time In Hrs Cumulative % Drug Release For Example 5 1 Not More Than 20% 4 30-50% 8 50-70% 16 Not Less Than 75% In -vivo Bioavailability Study: An Open Label, Balanced, Randomized, Single-Dose, Three-Treatment, Three-Sequence, Three-Period Crossover Oral Bioequivalence Study Of Reference product (Treatment A) 10 PRISTIQ@ (Extended release composition of Desvenlafaxine Succinate) 100 mg of Wyeth Pharmaceuticals Inc. Philadelphia, PA 19101 and Test product (Treatment B) Desvenlafaxine Benzoate Modified Release Tablet 100 mg formulated as per Example 13 under fasting conditions and food effect study of Desvenlafaxine Benzoate Modified Release Tablet 100 mg formulated as per example 13 administered under fasting 15 (Treatment B) and fed (Treatment C) conditions in Healthy, Adult, Human Male Subjects.

WO 2012/140577 PCT/IB2012/051761 40 The study was designed to demonstrate the similar clinical efficacy compared to Pristiq. The in-vivo bioavailability study in fasting state shows the results as shown in the Table 3 below: 5 Table 3: Comparative pharmacokinetic parameters of Example 13 vs Pristiq* 100 mg in Fasted state AUC (0- t) AUC (0-o) C. Product NameTwns ng. hr /ml ng. hr iml ng iml Desvenlafaxine Benzoate MR 5429.332 6140.836 249.504 5.943 Tablets 100 mug 10 Pristiq 100 mg 5762.351 6096.586 263.630 6.257 Conclusions: 15 Bioequivalence between Treatment A and B administered under fasting conditions: The 90% Confidence Interval of the relative geometric mean of Cm, AUC(o-t) and AUC(o_ y were found to be within the limit of 80 % to 125 %. Based on the results obtained, Desvenlafaxine Benzoate Modified Release Tablet 100mg formulated as per Example 13 20 and PRISTIQ® (Extended release composition of Desvenlafaxine Succinate) 100 mg of Wyeth Pharmaceuticals Inc. Philadelphia, PA 19101, are found to be bioequivalent in healthy human adult male subjects under fasting conditions. Food effect (Treatment B vs C) on Desvenlafaxine Benzoate Modified Release Tablet 25 100mg: Administration of Desvenlafaxine Benzoate Modified Release Tablets 100 mg with food had a minimal effect on drug absorption, resulting in an approximate 2 hour delay in Tmax. Cmax and AUC were comparable for Desvenlafaxine Benzoate Modified Release Tablets 100 mg when administered after a high-fat meal and under fasting condition as the ratios WO 20121140577 PCT/IB2012/051761 41 falls between 80-125%. Food is not expected to have significant clinical effect on the absorption (Cma and AUC) of Desvenlafaxine from Desvenlafaxine Benzoate Modified Release Tablets 100 mg. Desvenlafaxine Benzoate Modified Release Tablets 100 mg can be administered without regard to food. 5

Claims (4)

1. 3. The modified release pharmaceutical composition of claim 1, wherein Desvenlafaxine Beunzoate is characterized by a powder X-ray diffraction pattern 15 having peaks at about 54, 10735, 166, 18.0, 19.2. 23.32 0.2 degrees 29.
2. 4. The modified release pharimaceutical composition of clain 1, wherein Desveniafaxine Benzoate is characterized by powder X-ray diffraction patern having peaks at about 5.4, 9.5, 10.7. 16.1, 166. 17.3, 18.0, 19.2, 20.4, 21.5, 20 23.3, 24.9, 28.3, 2Q.9 Q 0.2 degrees 29
3. 5. A modified elease pharmaceutical composition comprisig Devenafaxine Benzoate, one or more release moding agen(s and one or more phrmaceutically acceptable excipient(s) therof where said composition 25 releases about 756 of Desvenlafaxine in 16 hours measured using USP Type I dissolution appnraws in 900 ml of 0.9% NaCI in water, at 100 rpm, 6, A modified release pharmaceutical composition comparing Desveniafaxine Benzoat, one or more release modifying agents) and one or mee 30 pharmaceudaally acceptable exipint) thereof wherin C andAUC of the modified release composition are within the limit of 80 % to 125 % of C and AUG of the extended release composition of Desveniafaxine Succinate.
4. 7. A modified rdease phannaceutical coinositn corising Iesvenkafaxine 5 Benzoate, one or more release modifying agents) and one or more pharmaceutically acceptable excipient() thereof wherein C and AUG of the Modified release composition are independent of food effect, & A modified release pharmaceutical composition according to claims 1, 5, 6 or 7 0 substantially as hereinbefore defined with reference to the Examples, excluding any comparative Examples.